Hanmi's Amodipine success to be resumed with Slimmer?

Hanmi has developed a modified new anti-obesity drug based on sibutramine (Reductil) expecting a similar market success perspective with Amodipine, another modified amlodipine preparation being remarkably succeeded in the market.

Amodipine, a modified amlodpine (Novarsc) made a great success with 50 billion won of sales (50.2 billion won of production in 2006) in 3 years after its market lau...